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Detection of prion seeding activity 
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Veronica Redaelli1,*, Edoardo Bistaffa1,2,*, Gianluigi Zanusso3,*, Giulia Salzano2, 
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Fatal Familial Insomnia (FFI) is a genetic prion disease caused by a point mutation in the prion 
protein gene (PRNP) characterized by prominent thalamic atrophy, diffuse astrogliosis and moderate 
deposition of PrPSc in the brain. Here, for the first time, we demonstrate that the olfactory mucosa (OM) 
of patients with FFI contains trace amount of PrPSc detectable by PMCA and RT-QuIC. Quantitative 
PMCA analysis estimated a PrPSc concentration of about 1 × 10−14 g/ml. In contrast, PrPSc was not 
detected in OM samples from healthy controls and patients affected by other neurodegenerative 
disorders, including Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. These 
results indicate that the detection limit of these assays is in the order of a single PrPSc oligomer/
molecule with a specificity of 100%.
Transmissible Spongiform Encephalopathies (TSEs) are a group of fatal and incurable neurodegenerative diseases 
that might present as sporadic, acquired or genetic conditions. The most common form of sporadic TSE is rep-
resented by the Creutzfeldt-Jakob disease (CJD)1,2. Acquired forms include variant CJD (vCJD) which is linked 
to the consumption of cattle infected with bovine spongiform encephalopathy (BSE)3,4. Genetic forms are asso-
ciated to mutations and insertions in the PRNP gene encoding the cellular prion protein (PrPC)5. Fatal Familial 
Insomnia (FFI) is caused by a point mutation at codon 178 of PRNP resulting in aspartic acid to asparagine 
substitution in coupling phase with methionine at polymorphic position 129 (D178N/129M)6. FFI is associated 
with sleep alterations, autonomic dysfunction, loss of weight and motor signs7. After symptoms onset, the disease 
usually leads to death within 2 years and no treatments are available at present8.
Although characterized by a great heterogeneity of clinical and neuropathological phenotypes, these diseases 
share a common infectious agent which is a conformationally altered form of the PrPC, known as PrPSc, which is 
able to induce the conformational conversion of PrPC into new PrPSc. Compared to PrPC, PrPSc has higher content 
in β -sheet structures, is insoluble in mild detergents and partially resistant to protease degradation. Thus, after 
digestion with proteinase K (PK), PrPC is completely digested while PrPSc shows a PK resistant core (27–30 kDa)9. 
Mutations in the PRNP gene might favor the process of PrPC misfolding and aggregation thus favoring the for-
mation of PrPSc.
Both PrPC and PrPSc can be variably glycosylated and give rise to diglycosylated, monoglycosylated and ung-
lycosylated species10. After PK digestion, only the unglycosylated band can migrate at around 21 kDa (type 1) 
or 19 kDa (type 2)1. The relative abundance of each PrP glycoform (glycoform ratio) and the electrophoretic 
mobility of the unglycosylated form enable a biochemical classification of different prion strains. For instance, the 
sporadic forms of CJD are generally characterized by a predominance of the monoglycosylated PrP band, with 
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unglycosylated PrP migrating at 21 kDa (sCJD-type1) or 19 kDa (sCJD-type2). BSE, vCJD and FFI are character-
ized by an abundance of the diglycosylated band with the unglycosylated one migrating at 19 kDa (type 2)3,8,11.
Recently, two innovative assays named Protein Misfolding Cyclic Amplification (PMCA) and Real Time 
Quaking-Induced Conversion (RT-QuIC) were generated to model the process of prion misfolding in vitro in an 
accelerated manner. PMCA12 consists of cycles of incubation and sonication of samples containing small amount 
of PrPSc in the presence of an excess of PrPC. This enables the exponential amplification of PrPSc, and can begin 
the reaction with the equivalent of a single molecule of PrPSc, which after amplification can give rise to billions 
of PrPSc molecules13. Therefore, PMCA analysis allowed to detect extremely low levels of PrPSc in urine14 and 
blood15,16 of patients with vCJD as well as in blood of sheep and primates experimentally infected with vCJD 
in preclinical stages17. RT-QuIC18 alternates phases of incubation to phases of vigorous shaking where soluble 
recombinant prion proteins (recPrP) are used as substrate for detecting femtomolar amounts of PrPSc. The reac-
tion is monitored by Thioflavin-T (ThT) fluorescence and enabled detection of PrP seeds in the cerebrospinal 
fluid (CSF) of patients with sporadic CJD (sCJD) or genetic forms of prion disease (e.g. GSS and FFI) either in the 
symptomatic19 or pre-symptomatic stage of the disease20,21. RT-QuIC has been further adapted to detect PrPSc in 
other tissues, such as the olfactory mucosa (OM) of patients suffering from sporadic CJD22. Taken together, these 
findings suggest that RT-QuIC and PMCA have a huge potential to detect trace-amount of PrPSc (≥ 1 femtogram) 
in peripheral tissues.
By taking advantage of recent observations23–25, we have optimized PMCA and RT-QuIC and extended their 
use for the analysis of OM samples collected from two patients with FFI, 16 patients with other neurodegenerative 
disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal Dementia (FTD) and 10 
healthy control (HC). Our results showed that both techniques were able to detect PrPSc in FFI-OM samples in 
the order of a single molecule with 100% specificity.
Results
PMCA and RT-QuIC efficiently detect PrPSc in serial dilutions of FFI brain homogenates. To 
assess whether PrPSc associated to FFI (FFI-PrPSc) was able to amplify by means of PMCA, we have performed 
spiking experiment diluting FFI brain homogenate (from 10−5 to 10−12 dilution of the brain) into 10% healthy 
bank vole brain homogenates (BvBH) carrying methionine at position 109 of the prion protein (M109). After one 
round of amplification, we could efficiently detect up to a 10−9 dilution while, after two rounds, we were able to 
amplify all dilutions (Fig. 1A). Similarly, dilutions of FFI brain homogenate were prepared in PBS and analyzed 
by means of RT-QuIC. The experiments were carried out using recombinant truncated form of the bank vole PrP 
(BvPrP(90-231)) as substrate and were seeded in triplicate with 2 μ L of each dilution (Fig. 1B). All reactions were 
performed at least three times by different operators. We could detect up to 10−9 dilution of PrPSc, while we did 
not efficiently detect any signal from higher dilutions. In particular, lower dilutions of brain homogenate induced 
a faster aggregation of BvPrP(90-231) (at around 8 hours), while intermediate dilutions induced aggregation after 
14 hours. A sample was considered positive when the mean of the highest two fluorescence values (AU) of the 
Figure 1. Serial dilutions of FFI brain homogenate (D178N/129M) were analyzed by means of PMCA and 
RT-QuIC for estimating their ability to detect PrPSc. (A) Ten % bank vole brain homogenates (BvBH) were 
spiked with serial dilution of FFI brain homogenate (from 10−5 to 10−12). The signal of PrPSc was assessed by 
means of Western blotting, after PK digestion, with the 6D11 antibody. Mw refers to the molecular weight. PrPC 
refers to normal bank vole brain homogenate not digested with PK. (B) Serial dilutions of FFI brain homogenate 
were analyzed by means of RT-QuIC reactions using BvPrP (90-231) as substrate. Average ThT fluorescence 
were plotted against time. AD brain homogenate (dilution 10−5) was used as negative control. BvPrP refers to 
unseeded recombinant protein.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:46269 | DOI: 10.1038/srep46269
replicates was higher than 10.000 AU and at least two out of three replicates crossed this value before 30 hours 
(see materials and methods for details). Samples that did not cross the threshold before 30 hours were considered 
negative. Brain homogenates of patient with AD and FTD were used as control and induced aggregation of BvPrP 
(90-231) after 30 hours, thus were considered negative (Fig. 1B).
PMCA and RT-QuIC can detect PrPSc from samples of olfactory mucosa. OM samples (n = 28) col-
lected from patients with FFI (n = 2), AD (n = 6), PD (n = 6), FTD (n = 4) and HC (n = 10) were blindly analyzed 
by means of PMCA and RT-QuIC. After three rounds of PMCA, we could detect PrPSc only in FFI-OM samples 
(Fig. 2A). All the other samples remained negative even after 7 rounds of amplification (Supplementary Fig. 1). 
Similarly, through RT-QuIC analysis we could detect prion seeding activity in both FFI-OM samples, while PrPSc 
was never detected in any of the OM belonging to the other patients analyzed (Fig. 2B). The final RT-QuIC 
reaction products were collected (at 30 hours) digested with PK and analyzed by means of Western blotting. As 
previously observed24, seeds collected from OM of patients with FFI, sporadic or iatrogenic forms of CJD were 
able to produce final RT-QuIC aggregates partially resistant to PK digestion and characterized by a molecular 
weight ranging from 14 to 18 kDa (Fig. 3A). On the contrary, OM samples collected from patients with PD, AD 
or healthy subjects did not produce any PK resistant aggregate. Brain homogenate of patients with FFI and iCJD 
were used as positive controls.
Estimation of PrPSc concentration in the olfactory mucosa by means of quantitative PMCA 
(qPMCA). To estimate the concentration of PrPSc present in the olfactory mucosa of an FFI subject, we have 
performed a quantitative PMCA, as previously described14. First, we have carefully estimated the concentration 
of PrPSc present in a FFI brain homogenate used to calibrate the PMCA reaction. The estimation was carried 
out by comparing the PrPSc signal by Western blot with a known concentration of human recombinant PrP 
(Supplementary Fig. 2A). By this procedure we calculated that PrPSc concentration in the 10% brain homoge-
nate of this patient was approximately 141 ng/ml. Thereafter, we have performed serial dilutions of this brain 
homogenate and used them for PrPSc detection after various rounds of PMCA. The results indicate that 1 round of 
PMCA enables to detect at around 10−10 to 10−11 g/ml of PrPSc. Two or more rounds of PMCA allowed detection 
of 10−13–10−14 g/ml of PrPSc (Supplementary Fig. 2B). Olfactory mucosa of FFI patient resulted positive after 2 
rounds of PMCA. According to our estimation the olfactory mucosa of this subject has a PrPSc concentration of 
1.41 × 10−14 g/ml.
Biochemical characterization of PMCA reaction products. The biochemical profile of the amplified 
PrPSc obtained from both FFI-OM samples was characterized by a predominance of the diglycosylated band 
of PrP with the unglycosylated one migrating at around 19 kDa1. As expected, PrPSc obtained from FFI brain 
homogenate showed a similar biochemical profile that did not change after amplification by PMCA (Fig. 3B)26. 
This pattern was then compared to that of PrPSc sCJD-type 1 or PrPSc sCJD-type 2 before and after PMCA. 
Although, sCJD brain homogenates showed their characteristic PrPSc biochemical profiles following PMCA the 
biochemical profile of both PrPSc changed and acquired a unique feature characterized by the prevalence of the 
diglycosylated band with the unglycosylated fragment migrating at around 19 kDa.
Figure 2. PrPSc detection in OM of FFI subjects using PMCA and RT-QuIC assays. (A) Representative image 
of PMCA analysis of olfactory mucosa samples (n = 28) that were blindly performed. After three rounds of 
amplification PrPSc could be detected in two samples (FFI-OM#1 and FFI-OM#2) that belong to subjects that 
were symptomatic at the time of OM collection. 10−5 and 10−8 refer to dilutions of FFI brain homogenate in 
PMCA substrate that were used as positive control for reaction. The signal of PrPSc was assessed by means of 
Western blotting, after PK digestion, with the 6D11 antibody. Numbers in the right indicate the position of Mw. 
PrPC refers to normal bank vole brain homogenate that was not digested with PK. Dashed line indicates cropped 
images from separate gels. (B) RT-QuIC reactions were seeded with olfactory mucosa specimens of all patients. 
FFI brain homogenate (FFI-BH 10−8) was used as positive control for the reaction. Two OM samples were found 
positive before the threshold set at 30 hours. Average ThT fluorescence were plotted against time.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:46269 | DOI: 10.1038/srep46269
Discussion
RT-QuIC and PMCA efficiently demonstrated the presence of PrPSc in urine14, CSF19, blood15 and olfactory 
mucosa22 of patients with prion diseases, at concentrations that are six orders of magnitude below the detection 
limits of the current diagnostic techniques, such as Western blot. RT-QuIC assay on OM samples obtained by 
nasal swabbing has been largely tested in patients with sporadic or genetic forms of CJD, showing a specificity 
of 100% and sensitivity of 97 and 75%, respectively, but never in patients with FFI or at risk of developing FFI.
In this work, we analyzed OM samples of 28 subjects 2 of whom carry the D178N mutation in the PRNP gene 
and already died with a clinical diagnosis of FFI. The other samples were collected from patients with different 
neurodegenerative disorders (including AD, PD and FTD) and healthy controls. RT-QuIC and PMCA analysis 
revealed the presence of PrPSc in both FFI-OM samples that were collected 4 and 10 months after the disease 
onset. In both cases, three rounds of amplification were enough to enable detection of PrPSc. Moreover, through 
quantitative PMCA we have estimated that the OM sample analyzed contained about 1 × 10−14 g/ml of PrPSc. 
This estimation should be carefully considered before being extended to other samples since it suffers from some 
limitations that might influence PMCA sensitivity. For instance, the efficiency of the nasal brushing itself and the 
dilution of samples before analysis might introduce technical variables to the assay. Even more important, the 
olfactory neurons are unique since they are replaced through life and the amount of PrPSc collected during each 
nasal brushing might also depend on this phenomenon27. PrPSc was not detected in patients affected by other neu-
rodegenerative diseases. At this point, we wondered whether PMCA was able to faithfully amplify the PrPSc orig-
inally detected in the OM of FFI patients. To this aim, we have performed a biochemical characterization of the 
amplified products and, after PK digestion, we observed a PrP banding profile characterized by a predominance 
of the diglycosylated species with the unglycosylated one migrating at around 19 kDa. This profile was compared 
to that of a PrPSc collected from the brain homogenate of a patient who died for FFI8. Both profiles were similar 
and suggested that PMCA of OM samples might be able to maintain the biochemical feature of the PrPSc typically 
associated to FFI. To confirm our observation, we decided to perform PMCA analysis in FFI brain homogenates 
and in two cases of sporadic sCJD-type 1 or sCJD-type 2 with PrPSc biochemical profiles different to that of FFI. 
Following PMCA amplification, FFI-PrPSc did not change its biochemical profile, while PrPSc associated to each 
sCJD type converted to a PrPSc glycotype characterized by a predominance of the diglycosylated band with the 
unglycosylated one migrating at 19 kDa (type 2). Therefore, we have realized that, even though our PMCA con-
ditions enable PrPSc amplification, the original biochemical features of the prion strain were not retained. Recent 
PMCA experiments23,28 revealed that the glycoform ratio or the electrophoretic mobility of different prion strains 
Figure 3. Amplified OM-PrPSc comparison with that of FFI or sCJD-type 1 and sCJD-type 2 brain 
homogenates. (A) Western blot of the final products of RT-QuIC reaction seeded with brain homogenates or 
olfactory mucosa from sCJD, iCJD, FFI, AD, PD patients and healthy controls (HC). Samples were digested 
with PK [50 μ g/mL] and immunoblot was probed with the C-terminal antibody SAF-84. Number in the right 
indicates the position of Mw. (B) Biochemical profile of amplified products (both brain homogenates and 
olfactory mucosa) was compared to that of FFI, sCJD-type 1 and sCJD-type 2 brain homogenates assessed 
before and after PMCA. FFI brain homogenate was concentrated 20-fold for PrPSc detection. The signal of PrPSc 
was assessed by means of Western blotting, after PK digestion, with the 6D11 antibody. Numbers in the right 
indicate the position of Mw: 21 kDa refers to type 1 PrPSc, while 19 kDa refers to type 2 PrPSc.
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are not faithfully maintained after amplification using bank vole homogenates as substrate for the reaction. These 
results seem to be corroborated by in vivo experiments which demonstrated that intracerebral inoculation of dif-
ferent prion strain (including sCJD-type 1 and type 2) in bank voles29 or transgenic mice expressing the bank vole 
prion protein25 with methionine at codon 109 (Tg109M) gave rise to PrPSc with electrophoretic mobilities similar 
to that of the original inoculum but with a glycoform ratio characterized by a predominance of the diglyco-
sylated PrP band30. All these results suggest that, although bank voles can amplify different strains of prion, they 
might amplify PrPSc with biochemical properties slightly different to that of the original prion strain. Certainly, 
additional factors other than PrP itself could play an important role in driving the fidelity of prion replication 
and further studies are necessary to clarify this intricate mechanism of amplification. PK digestion of RT-QuIC 
amplification products enabled detection of protease resistant recPrP useful for identifying reactions seeded with 
prion infected olfactory mucosa samples. However, differences in the Western blot banding profiles (between 
sCJD, iCJD or FFI) do not seem to have any correlation with distinct disease phenotypes.
Since the involvement of the olfactory system, including the olfactory bulb, in FFI has never been deeply 
investigated, we have hypothesized that PrPSc could have spread from the central nervous system (CNS) to the 
OM through axonal transport along nerve fibers, as it happens for the sporadic forms of CJD31. Otherwise, some 
mutations of the PrPC gene, especially the D178N which is located in the hydrophobic core of the protein, are 
known to reduce the stability of the protein which is subsequently more prone to misfold32,33. This process might 
be favored in the nasal cavity, which is constantly exposed to chemical and physical stress34 which predisposes 
PrPC to acquire less stable conformations, eventually leading to the formation of PrPSc. If this were the case, the 
presence of PrPSc in the OM is not directly linked to disease progression but instead represents a completely 
independent event.
Our results demonstrated that the OM collected from symptomatic FFI patients contain minimal amount of 
PrPSc. Therefore, considering the extremely high levels of sensitivity and specificity of PMCA and RT-QuIC, we 
are planning to investigate whether PrPSc might be detectable in subjects carrying the D178N mutation in the 
preclinical stage. There is only one study showing pre-symptomatic alterations in the thalamus of a D178N car-
rier who underwent to serial 18FDG-PET that was characterized by a selective hypometabolism in the thalamus 
13 months before the clinical onset. No correlations between thalamic dysfunction and presence of PrPSc were 
analyzed35. Prospective longitudinal studies will enable to evaluate whether detection of PrPSc in OM collected 
from subjects of a well characterized Italian FFI family, which is currently involved in a preventive clinical trial 
with doxycycline, might be used as quantifiable biomarker to monitor the effect of the drug on PrP replication 
and disease progression33.
Materials and Methods
Ethical approval. The study was approved by the institutional review board of Carlo Besta Neurological 
Institute and performed according to the guidelines approved by the ethics committee. Written informed con-
sent for participation in research was done in accordance with the Declaration of Helsinki (1964–2008) and the 
Additional Protocol on the Convention of Human Rights and Biomedicine concerning Biomedical Research 
(2005).
Olfactory mucosa brushing procedure. A step-by-step tutorial video of the nasal brushing procedure is 
available at: https://www.youtube.com/watch?v= wYb9W3u6uMY. This procedure was performed using flocked 
swabs (FLOQSwabsTM Copan Italia, Brescia, Italy), as previously described22,36.
Brain homogenates preparation. Frontal cortex of patients with Fatal Familial Insomnia (FFI-D178N), 
Alzheimer’s disease (AD), Frontotemporal Dementia (FTD) sporadic Creutzfeldt-Jakob disease (sCJD) and iat-
rogenic Creutzfeldt-Jakob disease (iCJD) were homogenized in phosphate buffer (pH 7.4, Sigma) at 10% (weight/
volume). Samples were centrifuged (Eppendorf Centrifuge) at 4 °C, 800 × g, 1 minute in order to remove cellular 
debris. Supernatant was collected and stored at − 80 °C for further use.
Olfactory mucosa cells collections. Olfactory mucosa (OM) cells were collected from the mid-part of 
the inferior turbinate by brushing with a cotton swab, after treating the nasal mucosa of the patients with a topi-
cal anesthetic. Cotton swab was subsequently immersed in saline solution and olfactory cells collected from the 
brush by means of vortexing.
Olfactory mucosa cells preparation for PMCA analysis. Olfactory mucosa cells were pelleted for 
20 minutes at 800 × g at 4 °C. The supernatant was removed and approximately 2 μ l of the pellet was collected 
and transferred into a tube containing 25 μ l of PBS. The latter was sonicated (approximately 280 W) with a 
Microsonicator QSonica (Q700) until the pellet was dispersed and 10 μ L of this solution was added to 90 μ L of 
specific PMCA substrate and subjected to several rounds of amplification.
Substrate preparation for PMCA analysis. Bank voles carrying the M109 PrP genotype were sacri-
ficed with carbon dioxide and immediately perfused using phosphate-buffered saline (PBS) plus 5 mM ethyl-
endiaminetetraacetic acid (EDTA, Sigma). Brains were collected and homogenized in conversion buffer (PBS, 
150 mM NaCl, 1% Triton X-100) at 10% (weight/volume). Heparin (100 μ g/mL, Sigma), digitonin (0.05%, Sigma) 
and 3 teflon beads were added to the homogenates to increase PMCA efficiency. To avoid contamination, perfu-
sion and brain homogenates were carried out in a prion-free laboratory.
PMCA procedure. PMCA was performed as previously reported36. Briefly, 10 μ L of sonicated olfactory 
mucosa samples was added to 90 μ L of fresh substrate and subjected to 96 cycles of PMCA with the use of a 
microsonicator (model Q700, Qsonica). Each cycle consisted of 29 minutes 30 seconds of incubation at 37–40 °C, 
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followed by a 30-second pulse of sonication set at a potency of 260–280 W. After one round of PMCA, an aliquot 
of the amplified material was diluted by a factor of 10 into fresh brain homogenate and an additional round was 
performed. Each sample was subjected to 7 rounds of PMCA. Considering our ultrasensitive level of amplifi-
cation, all PMCA reactions were prepared under rigorous prion-free conditions. Overall, in order to avoid any 
contamination, appropriate number of negative controls were added in each PMCA assay. No contamination or 
de novo generation of prions were observed.
SDS-PAGE and Western blotting. Ten microliters of final PMCA products was treated with 50 μ g/mL 
of PK (Invitrogen) for 1 hour at 37 °C under shaking (550 rpm). Digestion was stopped by the addition of 
LDS-PAGE loading buffer (Life Technologies), samples were heated at 100 °C for 10 minutes and loaded into 
12% Bolt Bis-Tris Plus gels (Life Technologies). Proteins were separated by means of SDS-PAGE, transferred onto 
Polyvinylidene difluoride (PVDF, Millipore) membrane and incubated with 5% (wt/vol) dry nonfat milk in 0.05% 
(vol/vol) Tween-20 (prepared in Tris-HCl) for 1 h at room temperature with shaking. PVDF membranes were 
finally incubated with anti-PrP antibody 6D11 (epitopes 93–109, Covance) and developed with chemilumines-
cent system (ECL Prime, GE Healthcare Amersham).
Ten microliters of RT-QuIC reaction products was digested with 50 μ g/mL of PK at 37 °C for 30 minutes 
under shaking (550 rpm). Digestion was stopped by the addition of LDS-PAGE loading buffer, samples were 
heated at 100 °C for 10 minutes and loaded into 17% Bolt Bis-Tris Plus gels. Proteins were separated by means of 
SDS-PAGE, transferred onto Polyvinylidene difluoride (PVDF) membrane and incubated with 5% (wt/vol) dry 
nonfat milk in 0.05% (vol/vol) Tween-20 (prepared in Tris-HCl) for 1 h at room temperature with shaking. PVDF 
membranes were finally incubated with anti-PrP antibody SAF-84 (epitopes 160–170, Spi Bio) and developed 
with chemiluminescent system (ECL Prime).
Recombinant PrP production for RT-QuIC analysis. Truncated Bank voles PrP (BvPrP(90-231)) 
construct was purchased from GenScript. The construct was expressed in Escherichia coli BL21 (DE3) cells 
(Stratagene). Freshly transformed overnight culture was inoculated into Luria Bertani (LB) medium and 100 μ g/mL 
ampicillin. At 0.8 OD600 expression was induced with isopropyl b-D galactopyranoside (IPTG) to a final 
concentration of 0.75 mM. Cells were grown in a BioStat-B plus fermentor (Sartorius). The cells were lysed 
by a homogenizer (PandaPLUS 2000) and the inclusion bodies were suspended in buffer containing 25 mM 
Tris-HCl, 5 mM EDTA, 0.8% TritonX100, pH 8, and then in bi-distilled water several times. Inclusion bodies 
containing BvPrP(90-231) were dissolved in 5 volumes of 8 M guanidine hydrochloride (GndHCl), loaded onto 
pre-equilibrated HiLoad 26/60 Superdex 200-pg column, and eluted in 25 mM Tris–HCl (pH 8), 5 mM ethylene-
diaminetetraacetic acid (EDTA), and 6 M GndHCl at a flow/rate of 2 mL/min. Proteins refolding was performed 
by dialysis against refolding buffer (20 mM sodium acetate and 0.005% NaN3 (pH 5.5)) using a Spectrapor mem-
brane. Purified protein was analyzed by SDS-polyacrylamide gel electrophoresis under reducing conditions and 
Western blot.
Olfactory mucosa cells preparation for RT-QuIC assay. Olfactory cells were collected from the brush 
by means of vortexing. The brush was then removed and the cells were pelleted for 20 minutes at 800 × g at 4 °C. 
The supernatant was removed, and approximately 2 μ l of the pellet was collected and transferred into a tube con-
taining 25 μ l of PBS. The latter was sonicated (approximately 280 W) until the pellet was dispersed and 2 μ L of 
this solution was further diluted in 18 μ L of freshly prepared PBS. Two μ L of the final solution was added to each 
reaction well.
Real-Time Quaking Induced Conversion procedure. After purification, aliquots of the recombinant 
BvPrP(90-231) were stored at − 80 °C in 10 mM phosphate buffer (pH 5.8). Before each test, the protein solu-
tion was allowed to thaw at room temperature and filtered through a 100 kDa Nanosep centrifugal device (Pall 
Corporation). The concentration of recPrP was determined by measuring the adsorbance at 280 nm. Samples 
were blindly analyzed at least three times (by different operators) in triplicate in a black 96-well optical flat bottom 
plate (Thermoscientific) and results showed a high degree of consistency.
The final reaction volume was 100 μ L and the reagents (Sigma) were concentrated as follow: 150 mM NaCl, 
0.002% SDS, 1X PBS, 1 mM EDTA, 10 μ M ThT and 0.1 mg recPrP ml−1. To avoid contamination, reaction mix was 
prepared in a prion-free laboratory. After the addition of 2 μ L of olfactory mucosa samples, the plate was sealed 
with a sealing film (Thermoscientific) and inserted into a FLUOstar OPTIMA microplate reader (BMG Labtech). 
The plate was shaken for 1 minute at 600 rpm (double orbital) and incubated for 1 minute at 55 °C. Fluorescence 
reading (480 nm) were taken every 15 minutes (30 flashes per well at 450 nm). Given the rapid response, a spe-
cific threshold was set to decrease the likelihood of false positives. A sample was considered positive if the mean 
of the highest two fluorescence values (AU) of the replicates was higher than 10.000 AU and at least two out of 
three replicates crossed the threshold that was set at 30 hours. This reaction cutoff was established because in all 
the experiments that were seeded with the brain homogenates of patients with Alzheimer’s disease, no positive 
RT-QuIC reactions were observed until after 30 hours. In rare occasions, we could observe the aggregation of 1 
replicate out of 3 before the threshold. In these cases, we have performed additional analysis of the samples in 
quadruplicate before considering it negative. The sample was confirmed negative if none or only one replicate 
(out of four) crossed the threshold before 30 hours. This allowed us to maximize the accuracy of the analysis thus 
reducing the risk of false positive or false negative results.
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